News | oneAMYLOIDOSISvoice

Alnylam gains EC approval for Amvuttra in ATTR amyloidosis

May 05, 2025

Facilitating an Early Diagnosis in ATTR-CM

Apr 05, 2025

Confirming the Benefit of SGLT2 Inhibitors in People With ATTR Amyloidosis, with Justin Riley Lam, MD

Apr 05, 2025

Senescence Accelerates the Occurrence of Dual Amyloidosis: Alzheimer's Disease and Wild-Type Transthyretin Amyloidosis

Apr 02, 2025

Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity

Apr 01, 2025

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Mar 20, 2025

RNAi Therapeutics Market Growth 2024-2025

Advancements in RNAi Therapeutics | 2024-2025 Update for Investors in Hospitals and HealthcareRNA interference (RNAi) therapeutics have garnered significant…

Mar 17, 2025

Alnylam’s Amvuttra Expected to Make Three in Crowded ATTR-CM Space

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

Mar 13, 2025

Allele-specific electrical genotyping for diagnosis of transthyretin amyloidosis

Feb 27, 2025

Amyloid plaque removal slows progression of Alzheimer's symptoms in early stages

Feb 25, 2025

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…

Subscribe to